Objective To investigate the clinical value of simultaneous assessment of cardiac troponin I,Btype natriuretic peptide,and C-reactive protein in prediction of long-term cardiac outcome after cardiac surgery.Methods 224 patients undergoing cardiac surgery were included and followed up within 12 months after surgery.Serial blood samples were drawn in all patients the day before surgery,at the end of surgery,and 6,24,and 120h after surgery.Major adverse cardiac events within 12 months after surgery were chosen as study endpoints and were defined as malignant ventricular arrhythmia,myccardial infarction,congestive heart failure,the need for myocardial revascularization,and/or death from cardiac cause.Predictive ability of each cardiac biomarker was assessed using logistic regression.Results Accuracies of C-reactive protein,cardiac troponin I,and B-type natriuretic peptide,considered as continuous variables to predict the occurrence of major adverse cardiac events were limited(area under receiver operating characteristic curve:0..54[0.47 ～0.60],P =0.42,0.62[0.55 ～0,68],P =0.01,and 0.68[0.61 ～0.74],P ＜0,001,respectively).When biomarkers were considered as 75％ specificity dichotomized variables,evaluated C-reactive protein(＞ 180mg/L),cardiac troponin I(＞ 3.5ng/ml),and B-type natriuretic peptide (＞ 880pg/ml)were independent predictors of major adverse cardiac events(odds ratio:2.14[1.03 ～4.49],P =0.043,2.37 [1.25 ～ 5.64],P =0.011,and 2.65 [1.16 ～ 4.85],P =0.018,respectively) in a multivariate model including the European System for Cardiac Operative Risk Evaluation score.Conclusion Simultaneous measurement of cardiac troponin I,B-type natriuretic peptide,and C-reactive protein improves the risk assessment of long-term adverse cardiac outcome after cardiac surgery.

Objective To study the inhibitory effect of Pharbitidis Semen on rat hepatoma induced by N-nitrosodiethylamine ( NDEA) . Methods SD rats were divided into normal control group, model control group and Pharbitidis Semen group. In model control group and Pharbitidis Semen group, 0. 01% NDEA was applied for 90 days to induce hepatoma, and rats in Pharbitidis Semen group concomitantly received feed containing 6% Pharbitidis Semen at the dosage of 40 g·kg-1 ·d-1 . Thirty days after the hepatoma inducement and Pharbitidis Semen administration, the rats were sacrificed to observe the pathological changes in liver, number of hepatoma nodules and liver weight. The changes of liver/body weight, serum alanine aminotransferase (ALT), γ-glutamyl transferase (γ-GT), and alkaline phosphatase (ALP) were compared. One-way ANOVA (LSD Test) was employed for statistical analysis. Results In the normal control group, the number of hepatoma nodules was 0. 0±0. 0, the liver weight was (9. 87±1. 30) g, the ratio of liver/body weight was (2. 62±0. 24)% and the level of serum ALT was (64. 10±12. 71) U·L-1,γ-GT was (0. 80± 0. 42) U·L-1, and ALP was (121. 20±37. 57) U·L-1. In the model control group, the number of hepatoma nodules was (27. 4±9. 5), the liver weight was (21. 38±7. 29) g, the ratio of liver/body weight was (5. 82±2. 31)%, the level of serum ALT was (175. 70±48. 75) U·L-1, γ-GT was (41. 80±15. 38) U·L-1, and ALP was (200. 50±35. 78) U·L-1. In the Pharbitidis Semen group, the number of hepatoma nodules was (8. 6± 5. 3), the liver weight was (13. 91±3. 55) g, the ratio of liver/body weight was (3. 86±0. 76)% and the level of serum ALT was (113.10±45.35) U·L-1, γ-GT was (13. 40± 6. 15) U·L-1, and ALP was (155. 80±30. 26) U·L-1. The results showed that all indices of Pharbitidis Semen group were higher than those of the normal control group, and lower than those of the model control group (P<0. 01 or P<0. 05). Conclusion Pharbitidis Semen can reduce NDEA-induced injury to the liver cells, and inhibit the overgrowth of the hepatoma.